Michael S. Gordon - Concepedia

Author

Michael S. Gordon

Also Known As

Clare, Robert, Dhan Chand, Gordon M., Gordon, Michael, Guthoff, Moritz, Jung, Hannes, LaDonna Malone, M Gordon, M S Gordon, M. Gordon

573

Publications

27.8K

Citations

H-Index

149

Concepts

All Affiliations

Pinnacle Oncology Hematology HonorHealth Sarah Cannon Dana-Farber Cancer Institute Memorial Sloan Kettering Cancer Center

About

Michael S. Gordon is an author at Pinnacle Oncology Hematology specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	116	12.9K
2	Health Sciences	19	24	2.3K
3	Engineering	2	2	63
4	Public Health	2	2	53
5	Social Sciences	1	1	10

Michael S. Gordon

214

Publications

26.3K

Citations

H-Index

Page 1

	Year	Citations
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Nature MedicineBiomarker TargetAnti-pd-l1 Antibody Mpdl3280aImmunologyPathology	2014	5.2K
Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid) Raymond P. Warrell, Stanley R. Frankel, Wilson H. Miller, New England Journal of Medicine	1991	1.3K
Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer Michael S. Gordon, Kim Margolin, Moshe Talpaz, Journal of Clinical Oncology	2001	915
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer Christophe Massard, Michael S. Gordon, Sunil Sharma, Journal of Clinical Oncology	2016	839
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma David F. McDermott, Meredith M. Regan, Joseph I. Clark, Journal of Clinical Oncology	2004	814
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer Leisha A. Emens, Cristina Cruz, Joseph P. Eder, JAMA Oncology	2018	774
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Michael B. Atkins, Michael J. Robertson, Michael S. Gordon, PubMed ImmunologyPharmacotherapyImmunotherapyInflammationHematological Malignancy	1997	590
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial Manish R. Patel, John Ellerton, Jeffrey R. Infante, The Lancet Oncology Urological ResearchUrologyMetastatic Urothelial CarcinomaUrologic Cancer EpidemiologyGenitourinary Cancer	2017	582
Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer Ryan B. Corcoran, Thierry André, Chloé E. Atreya, Cancer Discovery	2018	563
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, The Lancet Oncology Pharmacological StudyEfficacy DataPharmacologyClinical TrialsPharmacotherapy	2012	554

Page 1